Literature DB >> 21594697

Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica.

Sung-Min Kim1, Patrick Waters, Angela Vincent, Min Jin Go, Kyung Seok Park, Jung-Joon Sung, Kwang-Woo Lee.   

Abstract

Increased blood-brain barrier (BBB) disruption can be found in patients with neuromyelitis optica (NMO); however, its clinical implication and association with disability at acute attack remains obscure. The purpose of the study was to evaluate the clinical significance of BBB disruption and the subsequent cerebrospinal fluid (CSF)/serum IgG gradient in NMO. Retrospective analysis was made of acute-stage CSF samples from NMO (n = 40) and multiple sclerosis (MS; n = 26) patients. The CSF/serum IgG gradient (QIgG), albumin ratio (Qalb), and IgG index were calculated. Multivariate regression analysis was used to identify clinical and CSF variables associated with disability at acute attacks (extended disability scale score, EDSS) in both groups. The EDSS was significantly associated with the QIgG (p < 0.001), Qalb (p = 0.012), and number of cumulative attacks (p = 0.012) in NMO but not in MS with univariate analysis. Length of spinal cord involvement was also associated with EDSS in NMO (p = 0.030). However, multivariate analysis revealed that the QIgG was only significantly associated with EDSS in NMO (0.580; 95% CI -0.257, 0.961; p = 0.002). The QIgG was also highly associated with the Qalb in NMO (p < 0.001). The QIgG may reflect systemic IgG leakage into the CNS and is strongly associated with disability at acute attacks in NMO, suggesting that BBB disruption can aggravate disease activity by facilitating systemic IgG infiltration into the CNS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21594697     DOI: 10.1007/s00415-011-6086-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

Review 1.  Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.

Authors:  H Reiber; J B Peter
Journal:  J Neurol Sci       Date:  2001-03-01       Impact factor: 3.181

Review 2.  Multiple sclerosis in the Japanese population.

Authors:  Jun-ichi Kira
Journal:  Lancet Neurol       Date:  2003-02       Impact factor: 44.182

3.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

4.  Brain abnormalities in neuromyelitis optica.

Authors:  Sean J Pittock; Vanda A Lennon; Karl Krecke; Dean M Wingerchuk; Claudia F Lucchinetti; Brian G Weinshenker
Journal:  Arch Neurol       Date:  2006-03

5.  Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.

Authors:  Monika Bradl; Tatsuro Misu; Toshiyuki Takahashi; Mitsutoshi Watanabe; Simone Mader; Markus Reindl; Milena Adzemovic; Jan Bauer; Thomas Berger; Kazuo Fujihara; Yasuto Itoyama; Hans Lassmann
Journal:  Ann Neurol       Date:  2009-11       Impact factor: 10.422

6.  Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis.

Authors:  Patrick Waters; Sven Jarius; Edward Littleton; Maria Isabel Leite; Saiju Jacob; Bryony Gray; Ruth Geraldes; Thomas Vale; Anu Jacob; Jacqueline Palace; Susan Maxwell; David Beeson; Angela Vincent
Journal:  Arch Neurol       Date:  2008-07

Review 7.  Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.

Authors:  Sven Jarius; Friedemann Paul; Diego Franciotta; Patrick Waters; Frauke Zipp; Reinhard Hohlfeld; Angela Vincent; Brigitte Wildemann
Journal:  Nat Clin Pract Neurol       Date:  2008-03-11

8.  Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

Authors:  Samira Saadoun; Patrick Waters; B Anthony Bell; Angela Vincent; A S Verkman; Marios C Papadopoulos
Journal:  Brain       Date:  2010-01-04       Impact factor: 13.501

9.  "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica.

Authors:  Shoichi Ito; Masahiro Mori; Takahiro Makino; Sei Hayakawa; Satoshi Kuwabara
Journal:  Ann Neurol       Date:  2009-09       Impact factor: 10.422

Review 10.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

View more
  8 in total

1.  High-Throughput Screening Assay Identifies Berberine and Mubritinib as Neuroprotection Drugs for Spinal Cord Injury via Blood-Spinal Cord Barrier Protection.

Authors:  Yuki Suzuki; Shinsuke Nakagawa; Takeshi Endo; Akihito Sotome; Rufei Yuan; Tsuyoshi Asano; Satoko Otsuguro; Katsumi Maenaka; Norimasa Iwasaki; Ken Kadoya
Journal:  Neurotherapeutics       Date:  2022-09-30       Impact factor: 6.088

2.  Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.

Authors:  Sung-Min Kim; Junwoo Park; Sun Hee Kim; Su-Yeon Park; Jee Young Kim; Jung-Joon Sung; Kyung Seok Park; Kwang-Woo Lee
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

3.  Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica.

Authors:  Yong Guo; Stephen D Weigand; Bogdan F Popescu; Vanda A Lennon; Joseph E Parisi; Sean J Pittock; Natalie E Parks; Stacey L Clardy; Charles L Howe; Claudia F Lucchinetti
Journal:  Acta Neuropathol       Date:  2017-02-09       Impact factor: 17.088

4.  Neutrophils delay repair process in Wallerian degeneration by releasing NETs outside the parenchyma.

Authors:  Yasuhiro Yamamoto; Ken Kadoya; Mohamad Alaa Terkawi; Takeshi Endo; Kohtarou Konno; Masahiko Watanabe; Satoshi Ichihara; Akira Hara; Kazuo Kaneko; Norimasa Iwasaki; Muneaki Ishijima
Journal:  Life Sci Alliance       Date:  2022-08-12

5.  Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status.

Authors:  Sung-Min Kim; Patrick Waters; Mark Woodhall; Ji Won Yang; Hyeran Yang; Jee-Eun Kim; Jung-Joon Sung; Kyung Seok Park; Kwang-Woo Lee
Journal:  BMC Neurol       Date:  2014-04-29       Impact factor: 2.474

6.  Hydroxycholesterol Levels in the Serum and Cerebrospinal Fluid of Patients with Neuromyelitis Optica Revealed by LC-Ag+CIS/MS/MS and LC-ESI/MS/MS with Picolinic Derivatization: Increased Levels and Association with Disability during Acute Attack.

Authors:  Eunju Cha; Kang Mi Lee; Ki Duk Park; Kyung Seok Park; Kwang-Woo Lee; Sung-Min Kim; Jaeick Lee
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240

Review 7.  Differential diagnosis of neuromyelitis optica spectrum disorders.

Authors:  Sung-Min Kim; Seong-Joon Kim; Haeng Jin Lee; Hiroshi Kuroda; Jacqueline Palace; Kazuo Fujihara
Journal:  Ther Adv Neurol Disord       Date:  2017-05-24       Impact factor: 6.570

8.  Changes in mitochondrial function in patients with neuromyelitis optica; correlations with motor and cognitive disabilities.

Authors:  Forough Foolad; Fariba Khodagholi; Seyed Massood Nabavi; Mohammad Javan
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.